공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

폭스바이러스 감염증 : 파이프라인 리뷰

Poxviridae Infections - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 08월 상품 코드 372674
페이지 정보 영문 96 Pages
가격
US $ 2,000 ₩ 2,307,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,614,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,921,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


폭스바이러스 감염증 : 파이프라인 리뷰 Poxviridae Infections - Pipeline Review, H2 2016
발행일 : 2016년 08월 페이지 정보 : 영문 96 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

폭스바이러스 감염증은 폭스바이러스, 폭스바이러스과에 속하는 바이러스에 의한 감염증입니다. 징후는 피부 발진, 열, 발진, 근육통, 두통, 신체의 통증, 구토 등입니다. 치료에는 항바이러스제를 사용합니다.

폭스바이러스 감염증(Poxviridae Infections) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

폭스바이러스 감염증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • Bavarian Nordic A/S
  • BioFactura, Inc.
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • China Biologic Products, Inc.
  • CJ HealthCare Corp.
  • EpiVax, Inc.
  • N & N Pharmaceuticals Inc.
  • SIGA Technologies, Inc.
  • Takeda Pharmaceutical Company Limited
  • Tonix Pharmaceuticals Holding Corp.
  • Verrica Pharmaceuticals Inc.

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 16.10.31

Summary:

Global Markets Direct's, 'Poxviridae Infections - Pipeline Review, H2 2016', provides an overview of the Poxviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poxviridae Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxviridae Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Poxviridae Infections
  • The report reviews pipeline therapeutics for Poxviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Poxviridae Infections therapeutics and enlists all their major and minor projects
  • The report assesses Poxviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Poxviridae Infections

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Poxviridae Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poxviridae Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Poxviridae Infections Overview
  • Therapeutics Development
    • Pipeline Products for Poxviridae Infections - Overview
    • Pipeline Products for Poxviridae Infections - Comparative Analysis
  • Poxviridae Infections - Therapeutics under Development by Companies
  • Poxviridae Infections - Therapeutics under Investigation by Universities/Institutes
  • Poxviridae Infections - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Poxviridae Infections - Products under Development by Companies
  • Poxviridae Infections - Products under Investigation by Universities/Institutes
  • Poxviridae Infections - Companies Involved in Therapeutics Development
    • Bavarian Nordic A/S
    • BioFactura, Inc.
    • CEL-SCI Corporation
    • Chimerix, Inc.
    • China Biologic Products, Inc.
    • CJ HealthCare Corp.
    • EpiVax, Inc.
    • N & N Pharmaceuticals Inc.
    • SIGA Technologies, Inc.
    • Takeda Pharmaceutical Company Limited
    • Tonix Pharmaceuticals Holding Corp.
    • Verrica Pharmaceuticals Inc.
  • Poxviridae Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (plague + small pox) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 24a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BA-368 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brincidofovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-40011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Smallpox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Molluscum Contagiosum - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • small pox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • smallpox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • smallpox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tecovirimat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • varicella hyperimmune globulins - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIR-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIR-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VP-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Poxviridae Infections - Dormant Projects
  • Poxviridae Infections - Discontinued Products
  • Poxviridae Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
      • Apr 25, 2016: SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat
      • Mar 17, 2016: SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX
      • Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral
      • Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral
      • Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
      • Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
      • Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox
      • Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
      • Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
      • May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine
      • Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery
      • Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million
      • Dec 23, 2014: Chimerix Provides Recap of 2014 Events
      • Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Poxviridae Infections, H2 2016
  • Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Poxviridae Infections - Pipeline by Bavarian Nordic A/S, H2 2016
  • Poxviridae Infections - Pipeline by BioFactura, Inc., H2 2016
  • Poxviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016
  • Poxviridae Infections - Pipeline by Chimerix, Inc., H2 2016
  • Poxviridae Infections - Pipeline by China Biologic Products, Inc., H2 2016
  • Poxviridae Infections - Pipeline by CJ HealthCare Corp., H2 2016
  • Poxviridae Infections - Pipeline by EpiVax, Inc., H2 2016
  • Poxviridae Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016
  • Poxviridae Infections - Pipeline by SIGA Technologies, Inc., H2 2016
  • Poxviridae Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Poxviridae Infections - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
  • Poxviridae Infections - Pipeline by Verrica Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Poxviridae Infections - Dormant Projects, H2 2016
  • Poxviridae Infections - Dormant Projects (Contd..1), H2 2016
  • Poxviridae Infections - Dormant Projects (Contd..2), H2 2016
  • Poxviridae Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Poxviridae Infections, H2 2016
  • Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top
전화 문의
F A Q